#1 Clinical Trials Search in Europe

VERCIRNON

Clinical trials are investigating VERCIRNON in a small phase 1 study. The trial looks at how a PET radiotracer behaves in the body after VERCIRNON is given to healthy participants, with a focus on Crohn’s disease-related targets. The study aims to measure where the tracer goes and how strongly it binds in the abdomen.

Table of Contents

Trial overview

This article covers one clinical trial of VERCIRNON, identified as 2022-502843-36-00, which was a completed Phase 1 interventional study.[1] The study used a PET scan approach to examine where the radiotracer [11C]AZ14132516 goes in the body after VERCIRNON was given.[1]

Who participated

The trial enrolled 9 healthy participants.[1] Even though the participants were healthy, the study was linked to Crohn’s disease research because the condition was listed in the trial data.[1]

What was measured

The main results were standard uptake value (SUV) and standard uptake value ratio (SUVR) in regions of interest.[1] These scan measures help show how much tracer is taken up and how much total binding occurs to CCR9 in the body areas being studied.[1]

The brief summary says the study aimed to examine the distribution of [11C]AZ14132516 and its binding to CCR9 in anatomical regions of interest in the abdominal area.[1] In simple words, researchers wanted to see where the tracer traveled and how it behaved in the belly area on the scan.[1]

Study design and phase

This was an interventional study, which means researchers gave the study intervention and then observed the results.[1] It was in Phase 1, the earliest stage of clinical research, which is often used to gather first information about how a study test performs in people.[1]

Condition focus: Crohn’s disease

The only condition named in the source data was Crohn’s disease.[1] The trial did not describe treatment of symptoms; instead, it focused on imaging and binding measurements that may help researchers study this condition in the abdominal area.[1]

Trial ID Phase Condition studied Status Enrollment
2022-502843-36-00 Phase 1 Crohn’s disease Completed 9

FAQ

  • What is being studied in the VERCIRNON trial? The study is looking at how the PET radiotracer [11C]AZ14132516 is distributed in the body after VERCIRNON is given. It also measures how well the tracer binds to CCR9, a target found in the study areas.
  • Who took part in the trial? The trial enrolled healthy participants. The source data also mentions Crohn's disease because that condition is part of the study focus.
  • What phase is the VERCIRNON trial? This is a Phase 1 trial. Phase 1 studies are usually early studies that help researchers learn about how a test is handled in the body and what it shows in people.
  • What condition is this trial related to? The trial is related to Crohn's disease. The study examines tracer binding in abdominal regions of interest, which may help researchers study this condition.
  • What results were measured in the study? The main results were standard uptake value (SUV) and standard uptake value ratio (SUVR). These are scan measurements that show how much tracer is taken up and how strongly it binds in the areas being studied.

Ongoing Clinical Trials on VERCIRNON

  • A study using the radiotracer vercirnon to examine its distribution in the body of healthy participants for research on Crohn’s disease

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

Glossary

  • Clinical trial: A research study in people that tests a medical approach under planned conditions.
  • Phase 1: An early trial phase that helps researchers learn basic information about a study treatment or test in people.
  • Interventional study: A study where researchers give a treatment or test and then measure what happens.
  • Healthy participants: People who do not have the disease being studied and who join a study to help researchers learn how a test behaves.
  • Crohn's disease: A long-term condition that causes inflammation in the digestive tract.
  • PET study: A study using positron emission tomography, a scan that helps show where a tracer goes in the body.
  • Radiotracer: A small amount of radioactive material used in imaging to help doctors or researchers see body processes.
  • CCR9: A target measured in the study; the trial looked at how strongly the tracer bound to this target.
  • Standard uptake value (SUV): A scan measurement that shows how much of the tracer is taken up in a chosen area.
  • Standard uptake value ratio (SUVR): A measurement that compares tracer uptake in one area with another area to help show binding.
  • Region of interest: A specific body area that researchers choose to measure on a scan.
  • Abdominal area: The belly area, where the study looked at anatomical regions of interest.

References

  1. https://clinicaltrials.gov/study/2022-502843-36-00